Alpha Cognition (NASDAQ:ACOG - Get Free Report) is expected to release its earnings data before the market opens on Wednesday, April 2nd. Analysts expect Alpha Cognition to post earnings of ($1.50) per share for the quarter. Investors that are interested in participating in the company's earnings conference call can do so using this link.
Alpha Cognition Stock Performance
ACOG traded up $0.22 on Friday, reaching $5.53. The company had a trading volume of 20,774 shares, compared to its average volume of 79,628. Alpha Cognition has a fifty-two week low of $4.66 and a fifty-two week high of $7.00. The firm has a market cap of $88.59 million, a PE ratio of -2.16 and a beta of 2.50. The firm's fifty day simple moving average is $5.85.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on ACOG. Raymond James upgraded Alpha Cognition to a "moderate buy" rating in a research report on Tuesday. HC Wainwright assumed coverage on shares of Alpha Cognition in a research report on Tuesday, March 18th. They set a "buy" rating and a $20.00 target price on the stock.
Check Out Our Latest Stock Analysis on Alpha Cognition
Alpha Cognition Company Profile
(
Get Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
See Also
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.